Compare Dr. Reddys with GSK Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DR. REDDYS LAB vs GSK PHARMA - Comparison Results

DR. REDDYS LAB     Change

Dr. Reddy's is a leading pharmaceutical company in the country with presence across the value chain. While the global generics business accounted for 69% of total revenues in FY12, the PSAI business (Pharma Services and Active Ingredients - PSAI) con... More

GSK PHARMA 
   Change

GSK Pharma is one of the leading MNC pharma companies in the Indian market. It is a 50.7% subsidiary of GlaxoSmithKline Plc, one of the world's largest pharma companies. GSK Pharma's product portfolio boasts of some of the leading brands like Augment... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DR. REDDYS LAB GSK PHARMA DR. REDDYS LAB/
GSK PHARMA
 
P/E (TTM) x 21.5 54.2 39.7% View Chart
P/BV x 3.2 11.4 28.2% View Chart
Dividend Yield % 0.7 1.4 52.9%  

Financials

 DR. REDDYS LAB   GSK PHARMA
EQUITY SHARE DATA
    DR. REDDYS LAB
Mar-19
GSK PHARMA
Mar-19
DR. REDDYS LAB/
GSK PHARMA
5-Yr Chart
Click to enlarge
High Rs2,8753,595 80.0%   
Low Rs1,8881,253 150.7%   
Sales per share (Unadj.) Rs930.2184.7 503.8%  
Earnings per share (Unadj.) Rs117.426.3 446.6%  
Cash flow per share (Unadj.) Rs185.829.2 637.0%  
Dividends per share (Unadj.) Rs20.0020.00 100.0%  
Dividend yield (eoy) %0.80.8 101.8%  
Book value per share (Unadj.) Rs844.4126.3 668.5%  
Shares outstanding (eoy) m166.07169.40 98.0%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x2.613.1 19.5%   
Avg P/E ratio x20.392.2 22.0%  
P/CF ratio (eoy) x12.883.1 15.4%  
Price / Book Value ratio x2.819.2 14.7%  
Dividend payout %17.076.1 22.4%   
Avg Mkt Cap Rs m395,496410,626 96.3%   
No. of employees `00022.05.0 442.9%   
Total wages/salary Rs m33,5625,372 624.8%   
Avg. sales/employee Rs Th7,032.86,306.7 111.5%   
Avg. wages/employee Rs Th1,527.91,083.1 141.1%   
Avg. net profit/employee Rs Th887.7898.0 98.9%   
INCOME DATA
Net Sales Rs m154,48231,281 493.8%  
Other income Rs m3,3751,023 329.9%   
Total revenues Rs m157,85732,304 488.7%   
Gross profit Rs m31,7826,009 528.9%  
Depreciation Rs m11,348486 2,335.0%   
Interest Rs m8896 14,816.7%   
Profit before tax Rs m22,9206,540 350.5%   
Minority Interest Rs m00-   
Prior Period Items Rs m4380-   
Extraordinary Inc (Exp) Rs m0287 0.0%   
Tax Rs m3,8582,373 162.6%   
Profit after tax Rs m19,5004,454 437.8%  
Gross profit margin %20.619.2 107.1%  
Effective tax rate %16.836.3 46.4%   
Net profit margin %12.614.2 88.7%  
BALANCE SHEET DATA
Current assets Rs m111,10120,061 553.8%   
Current liabilities Rs m58,97314,543 405.5%   
Net working cap to sales %33.717.6 191.3%  
Current ratio x1.91.4 136.6%  
Inventory Days Days7957 139.8%  
Debtors Days Days9414 670.0%  
Net fixed assets Rs m101,24514,343 705.9%   
Share capital Rs m8301,694 49.0%   
"Free" reserves Rs m139,40619,704 707.5%   
Net worth Rs m140,23621,398 655.4%   
Long term debt Rs m22,0002 1,100,000.0%   
Total assets Rs m224,65639,113 574.4%  
Interest coverage x26.81,091.0 2.5%   
Debt to equity ratio x0.20 167,846.5%  
Sales to assets ratio x0.70.8 86.0%   
Return on assets %9.111.4 79.6%  
Return on equity %13.920.8 66.8%  
Return on capital %14.931.9 46.8%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m88,673534 16,605.4%   
Fx outflow Rs m19,1047,091 269.4%   
Net fx Rs m69,569-6,557 -1,061.0%   
CASH FLOW
From Operations Rs m28,7043,994 718.7%  
From Investments Rs m-7,727-1,433 539.1%  
From Financial Activity Rs m-21,326-3,584 595.1%  
Net Cashflow Rs m-314-1,023 30.7%  

Share Holding

Indian Promoters % 25.5 0.0 -  
Foreign collaborators % 0.0 50.7 -  
Indian inst/Mut Fund % 5.4 10.2 52.9%  
FIIs % 35.3 23.8 148.3%  
ADR/GDR % 18.5 0.0 -  
Free float % 15.3 15.4 99.4%  
Shareholders   75,885 102,036 74.4%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DR. REDDYS LAB With:   STERLING BIOTECH  SANOFI INDIA  ALEMBIC PHARMA  SHASUN PHARMA  PFIZER  

Compare DR. REDDYS LAB With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Indian Stock Markets Remain in Green This Week: Is the Rebound Here?(Podcast)

After a long period of underperformance, stock markets traded in green territory throughout the week. So, is this is a trend reversal and is the bottom forming in the market?

Related Views on News

GSK PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 28.1% (Quarterly Result Update)

Jul 24, 2019 | Updated on Jul 24, 2019

For the quarter ended June 2019, GSK PHARMA has posted a net profit of Rs 1 bn (up 28.1% YoY). Sales on the other hand came in at Rs 8 bn (up 7.1% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

GSK PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Jun 24, 2019 | Updated on Jun 24, 2019

Here's an analysis of the annual report of GSK PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of GSK PHARMA. Also includes updates on the valuation of GSK PHARMA.

GSK PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 16.6% (Quarterly Result Update)

May 21, 2019 | Updated on May 21, 2019

For the quarter ended March 2019, GSK PHARMA has posted a net profit of Rs 1 bn (up 16.6% YoY). Sales on the other hand came in at Rs 8 bn (up 0.3% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

GSK PHARMA Announces Quarterly Results (3QFY19); Net Profit Up 26.0% (Quarterly Result Update)

Feb 5, 2019 | Updated on Feb 5, 2019

For the quarter ended December 2018, GSK PHARMA has posted a net profit of Rs 1 bn (up 26.0% YoY). Sales on the other hand came in at Rs 8 bn (up 17.3% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

DR. REDDYS LAB Announces Quarterly Results (3QFY19); Net Profit Up 67.0% (Quarterly Result Update)

Feb 4, 2019 | Updated on Feb 4, 2019

For the quarter ended December 2018, DR. REDDYS LAB has posted a net profit of Rs 5 bn (up 67.0% YoY). Sales on the other hand came in at Rs 39 bn (up 0.8% YoY). Read on for a complete analysis of DR. REDDYS LAB's quarterly results.

More Views on News

Most Popular

My 3 Best Small-cap Stocks to Get Rich in this Market Rebound(Profit Hunter)

Oct 14, 2019

This is once in a decade opportunity to make a killing from smallcap rebound.

Finally, Is the Share Price of Yes Bank Ready for a Rebound?(The 5 Minute Wrapup)

Oct 7, 2019

Here's what every individual investor must know about Yes Bank...

Two Stocks to Buy in the Great Indian Festival(Profit Hunter)

Oct 11, 2019

Discounts are not just limited to E-tailers. You can buy stocks at 50% off too. Here are two stocks to buy now.

Buy these 3 Stocks for Rebound Riches

Oct 18, 2019

Equitymaster's smallcap guru and editor of Hidden Treasure, Richa Agarwal, talks to us about the rebound in the stock market, and the best stocks to profit from it. Listen in...

The One Stock I Like in this Market(The 5 Minute Wrapup)

Oct 10, 2019

There are rare periods in markets when you get good quality stocks at attractive valuations. Is this one such period?

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

DR. REDDYS LAB SHARE PRICE


Oct 18, 2019 (Close)

TRACK DR. REDDYS LAB

  • Track your investment in DR. REDDYS LAB with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

DR. REDDYS LAB 5-YR ANALYSIS

COMPARE DR. REDDYS LAB WITH

MARKET STATS